Subtopic Deep Dive
Monoclonal Antibody Therapy Cancer
Research Guide
What is Monoclonal Antibody Therapy Cancer?
Monoclonal antibody therapy for cancer uses engineered antibodies targeting tumor antigens like HER2, EGFR, and PD-1/PD-L1 to inhibit tumor growth in solid and hematologic malignancies.
Trastuzumab combined with chemotherapy improves survival in HER2-overexpressing metastatic breast cancer (Slamon et al., 2001, 11374 citations). Köhler and Milstein (1975) established hybridoma technology for producing monoclonal antibodies (17068 citations). Yarden and Sliwkowski (2001) mapped the ErbB signaling network targeted by these therapies (6831 citations).
Why It Matters
Trastuzumab plus chemotherapy extended median survival by 5 months in HER2-positive breast cancer patients (Slamon et al., 2001). Fc receptor modulation enhances antibody-dependent cytotoxicity against tumors (Clynes et al., 2000). Ki-67 monoclonal antibody enables proliferation assessment in cancer diagnostics (Gerdes et al., 1984). These therapies improve response rates in clinical trials for breast cancer and other HER2-driven malignancies.
Key Research Challenges
HER2 Therapy Hepatotoxicity
Trastuzumab causes rare liver toxicity in breast cancer patients (Vucicevic et al., 2013, 4416 citations). Monitoring and risk factors remain unclear. Dose adjustments are needed to balance efficacy and safety.
Tumor Resistance Mechanisms
ErbB signaling networks drive resistance to HER2-targeted mAbs (Yarden and Sliwkowski, 2001, 6831 citations). Combination regimens are explored but lack predictors. Fc receptor variations reduce cytotoxicity (Clynes et al., 2000).
Proliferation Marker Specificity
Ki-67 antibody detects nuclear antigens in proliferating cells but expression phases need clarification (Gerdes et al., 1984, 4191 citations). Standardization improves prognostic accuracy in malignancies. Validation across cancer types is ongoing.
Essential Papers
Continuous cultures of fused cells secreting antibody of predefined specificity
Georges Köhler, César Milstein · 1975 · Nature · 17.1K citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · 2001 · New England Journal of Medicine · 11.4K citations
Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.
Untangling the ErbB signalling network
Yosef Yarden, Mark X. Sliwkowski · 2001 · Nature Reviews Molecular Cell Biology · 6.8K citations
Trastuzumab-Induced Hepatotoxicity: A Case Report
D. Vucicevic, Elizabeth J. Carey, Nina J. Karlin · 2013 · Breast Care · 4.4K citations
<b><i>Background: </i></b>Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overexpression. There are...
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
Johannes Gerdes, Hilmar Lemke, H. Baisch et al. · 1984 · The Journal of Immunology · 4.2K citations
Abstract The monoclonal antibody Ki-67 detects a nuclear antigen that is present only in proliferating cells. The aim of the present investigation was to clarify whether the Ki-67 nuclear antigen i...
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).
J L Cordell, Brunangelo Falini, Wendy N. Erber et al. · 1984 · Journal of Histochemistry & Cytochemistry · 3.2K citations
A murine monoclonal antibody specific for calf intestinal alkaline phosphatase has been prepared and used in an unlabeled antibody bridge technique for labeling monoclonal antibodies. This procedur...
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
Johannes Gerdes, Ulrich Schwab, Hilmar Lemke et al. · 1983 · International Journal of Cancer · 2.8K citations
Abstract The production of a mouse monoclonal antibody, Ki‐67, is described. The Ki‐67 antibody recognized a nuclear antigen present in proliferating cells, but absent in resting cells. Immunostain...
Reading Guide
Foundational Papers
Start with Köhler and Milstein (1975) for hybridoma origins, Slamon et al. (2001) for trastuzumab clinical proof, Yarden and Sliwkowski (2001) for HER2 signaling basics.
Recent Advances
Vucicevic et al. (2013) on trastuzumab hepatotoxicity; Gerdes et al. (1984) updates on Ki-67 for proliferation monitoring in trials.
Core Methods
Hybridoma fusion (Köhler and Milstein, 1975), APAAP complexes for detection (Cordell et al., 1984), Ki-67 immunostaining for cell cycle analysis (Gerdes et al., 1984).
How PapersFlow Helps You Research Monoclonal Antibody Therapy Cancer
Discover & Search
Research Agent uses searchPapers('trastuzumab HER2 breast cancer resistance') to find Slamon et al. (2001), then citationGraph reveals 11k+ citing papers on combinations, and findSimilarPapers uncovers Yarden and Sliwkowski (2001) for signaling insights.
Analyze & Verify
Analysis Agent applies readPaperContent on Slamon et al. (2001) to extract survival data, verifyResponse with CoVe checks claims against 50+ citing papers, and runPythonAnalysis plots Kaplan-Meier curves from extracted stats using matplotlib for efficacy verification. GRADE grading scores evidence as high for trastuzumab benefits.
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms from Yarden papers, flags contradictions in Fc receptor roles (Clynes 2000), then Writing Agent uses latexEditText for review drafting, latexSyncCitations for 20+ refs, and latexCompile generates polished manuscript.
Use Cases
"Extract and plot survival curves from Slamon trastuzumab trial data"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib plots HR/OR stats) → matplotlib survival plot exported as figure.
"Draft LaTeX review on HER2 mAb combinations with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Slamon/Yarden refs) → latexCompile → PDF review with figures.
"Find GitHub repos analyzing Ki-67 proliferation data"
Research Agent → searchPapers('Ki-67 Gerdes') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → repo with cell cycle analysis scripts.
Automated Workflows
Deep Research workflow scans 50+ HER2 mAb papers via searchPapers → citationGraph → structured report on efficacy/resistance (Slamon et al.). DeepScan applies 7-step CoVe analysis to Vucicevic hepatotoxicity case with GRADE scoring. Theorizer generates hypotheses on ErbB-Fc synergies from Yarden and Clynes papers.
Frequently Asked Questions
What defines monoclonal antibody therapy for cancer?
Engineered mAbs target tumor antigens like HER2 to block signaling and induce cytotoxicity in malignancies (Slamon et al., 2001).
What are key methods in mAb cancer therapy research?
Hybridoma production (Köhler and Milstein, 1975), APAAP immunolabeling (Cordell et al., 1984), and Ki-67 proliferation assays (Gerdes et al., 1984).
What are major papers?
Köhler and Milstein (1975, 17068 citations) for hybridomas; Slamon et al. (2001, 11374 citations) for trastuzumab; Yarden and Sliwkowski (2001, 6831 citations) for ErbB networks.
What open problems exist?
Resistance to HER2 mAbs (Yarden and Sliwkowski, 2001), hepatotoxicity risks (Vucicevic et al., 2013), and optimizing Fc-mediated cytotoxicity (Clynes et al., 2000).
Research Monoclonal and Polyclonal Antibodies Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Monoclonal Antibody Therapy Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers